ACADIA

Acadia Pharmaceuticals Inc. of caring warriors strives to make brighter moments possible for patients and their loved ones. For over 25 years, it has been at the forefront of healthcare, bringing critical solutions to those who need them the most and deserve it. It developed and marketed the first and only FDA-approved treatment for Parkinson's disease psychosis hallucinations and delusions. Late-stage research is concentrating on dementia-related psychosis, negative symptoms of schizophrenia, and Rett syndrome. In addition, it is investigating novel approaches to pain management, cognition, and neuropsychiatric symptoms in central nervous system disorders in early-stage clinical research.